Understanding the FDA Approved New Drug, Selinexor and its Use in Multiple Myeloma

Understanding the FDA Approved New Drug, Selinexor and its Use in Multiple Myeloma
August 29, 2019
Upcoming / RECENT Talks

Understanding the FDA Approved New Drug, Selinexor and its Use in Multiple Myeloma

with Dr. Dan Toby Vogl
Sept 4, 2019, 3 PM ET
Recently, the FDA approved a new cancer drug called Selinexor. This drug has been found to be successful in treating multiple myeloma in patients who have exhausted all other existing treatment options. Selinexor works on a different mechanism compared to other drugs. It enters a cell and targets mechanisms that move molecules into and out of the cell. We are talking to Dr. Dan Vogl, who lead the Phase II studies on Selinexor, on how the drug works, how it should be used, potential side effects and who should consider using it.
Dr. Dan Toby Vogl
Gary Petersen
Cynthia Chmielewski
Jack Aiello
Priya Menon
Sept 3, 2019, 2 PM ET
Nearly all patients with multiple myeloma first develop one of its precursor conditions. People with these conditions do not have any symptoms, and they are told to watch and wait to see if they develop multiple myeloma. Currently, there are no treatments that prevent the progression of myeloma precursor conditions. To overcome this, researchers need to understand changes happening at the molecular level and identify potential targets for treatment. Dr. Irene Ghobrial of Dana Farber Cancer Institute is talking to us about the new PROMISE study, the biggest myeloma screening study ever run to help prevent myeloma before it begins and share how you can join the study and help in research.

Dr. Irene Ghobrial
Tiffany H Williams
Misty Callahan
Dana Holmes
Priya Menon 
August 15, 2019, 2 PM ET
Precision medicine is an emerging approach in cancer treatment and prevention. It is a shift away from a one-size-fits-all approach and requires sharing of information across research settings and community. Precision Medicine's central principle revolves around the ability to identify personal gene characteristics and match them to specific treatment options. We are exploring advances and challenges of precision medicine in cancer care with Dr. Luke Gilbert and Dr. Eric Collisson of UCSFs Helen Diller Family Comprehensive Cancer Center. 


Dr. Eric Collisson 
Dr. Luke Gilbert
Heidi Floyd
Adam Hayden
Priya Menon
For any of the talks dial-in to 718-664-6574 to participate and ask a question LIVE On-Air! Only 50 callers permitted at one time so HURRY!
Our Picks